Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-XEN1101 · 1 trial · 1 indication
Cumulative amount of total radioactivity excreted in urine and feces combined (CumAe(total)) and expressed as a % of the radioactive dose administered (Cum%Ae(total)) following oral administration of 14C-XEN1101
| Arm | Type | Description |
|---|---|---|
| Drug: (14C)-XEN1101 | EXPERIMENTAL | Subjects will receive oral 14C-XEN1101 under fed conditions. |
| Name | Type | Description |
|---|---|---|
| 14C-XEN1101 | DRUG | Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101 |
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kg/m2 * Must be willing and able to communicate and participate in the whole study * Provide written informed consent * Adhere to the specified contraception requirements Key Exclusion Criteria: * Subjects who have received any inves...
14C-XEN1101 is a carbon-14 radiolabeled version of the small molecule XEN1101, developed by Xenon Pharmaceuticals Inc. (ticker: XENE). It is used in clinical research to study how the drug is absorbed, metabolized, and excreted in the body. The radiolabel allows researchers to track the drug and its breakdown products.
14C-XEN1101 is being developed by Xenon Pharmaceuticals Inc., a biopharmaceutical company that trades under the ticker symbol XENE. Xenon is focused on developing therapies for neurological disorders. The company conducted a Phase 1 trial of 14C-XEN1101 to study its metabolism and excretion.
14C-XEN1101 has completed a Phase 1 clinical trial. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 trial was a single-dose mass balance study conducted in healthy volunteers.
14C-XEN1101 has been studied in one completed Phase 1 clinical trial, NCT04952467, titled "Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101." The trial enrolled 6 healthy male volunteers in the United Kingdom and was completed. No active trials are currently listed.
14C-XEN1101 is used in clinical research to study the mass balance, metabolic profile, and excretion pathways of the drug XEN1101. It is not a therapeutic treatment itself but a radiolabeled tracer used in a Phase 1 trial with healthy volunteers to understand how the body processes the drug.